Yusuke Amanuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yusuke Amanuma has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chie Kudo-Saito
Department of Immune Medicine, National Cancer Center Research Institute, Tokyo, Japan
13 shared publications - Hirokazu Shoji
Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
13 shared publications - Hiroshi Imazeki
National Cancer Center Hospital
13 shared publications - Kai Tsugaru
Keio University Hospital 4 Division of Gastroenterology and Hepatology Tokyo, Japan
13 shared publications - Kei Muro
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
13 shared publications - Kengo Nagashima
Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan
13 shared publications
Latest Publications
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Relationship between proteomic and ELISA data (related to Figure 1)
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Relationship between proteomic and ELISA data (related to Figure 1)
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Blocking ANGPTL3 synergistically enhances anti-PD1 therapeutic efficacy in mouse tumor models. BALB/c mice were subcutaneously (5 × 105) implanted with Colon26 cells, and received intraperitoneal injection of anti-ANGPTL3 mAb, anti-PD1 mAb, or mIgG as a control at 10 mg/kg on days 3 and 10 after tumor implantation (n = 5). On day 17, the subcutaneous tumor and spleen were harvested randomly from three of 10 mice for assays. A, Suppression of tumor growth by treatments (n = 10). Open circles, mIgG control; closed circles, anti-ANGPTL3 mAb; and closed triangles, anti-PD1 mAb. Gray diamonds, anti-ANGPTL3 mAb and anti-PD1 mAb. B, Dramatical increase of tumor-infiltrating lymphocytes (TIL) by anti-ANGPTL3/-PD1 combination therapy. Tumor-infiltrating lymphocytes were analyzed by flow cytometry (n = 3). C, Increase of SPCs by treatments. SPCs were analyzed by flow cytometry (n = 3). D, Enhancement of the cytotoxic activity of splenic CD8+ T cells by anti-ANGPTL3/-PD1 combination therapy. AH1-prestimulated CD8+ T cells were cocultured with Colon26 cells as a target at effector:target (E:T) ratio = 40:1 for 4 hours (n = 3). Splenic DX5+ NK cells were also cocultured with Yac1 cells as a target at E:T ratio = 20:1 for 4 hours (n = 3). Graphs show means ± SDs. **, P < 0.05 vs. mIgG control analyzed by the Mann–Whitney U test, two-way ANOVA, or one-way ANOVA. Representative data of an experiment of three independent experiments with consistent results. aANGPTL3, anti-ANGPTL3; aPD1, anti-PD1.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Blocking ANGPTL3 synergistically enhances anti-PD1 therapeutic efficacy in mouse tumor models. BALB/c mice were subcutaneously (5 × 105) implanted with Colon26 cells, and received intraperitoneal injection of anti-ANGPTL3 mAb, anti-PD1 mAb, or mIgG as a control at 10 mg/kg on days 3 and 10 after tumor implantation (n = 5). On day 17, the subcutaneous tumor and spleen were harvested randomly from three of 10 mice for assays. A, Suppression of tumor growth by treatments (n = 10). Open circles, mIgG control; closed circles, anti-ANGPTL3 mAb; and closed triangles, anti-PD1 mAb. Gray diamonds, anti-ANGPTL3 mAb and anti-PD1 mAb. B, Dramatical increase of tumor-infiltrating lymphocytes (TIL) by anti-ANGPTL3/-PD1 combination therapy. Tumor-infiltrating lymphocytes were analyzed by flow cytometry (n = 3). C, Increase of SPCs by treatments. SPCs were analyzed by flow cytometry (n = 3). D, Enhancement of the cytotoxic activity of splenic CD8+ T cells by anti-ANGPTL3/-PD1 combination therapy. AH1-prestimulated CD8+ T cells were cocultured with Colon26 cells as a target at effector:target (E:T) ratio = 40:1 for 4 hours (n = 3). Splenic DX5+ NK cells were also cocultured with Yac1 cells as a target at E:T ratio = 20:1 for 4 hours (n = 3). Graphs show means ± SDs. **, P < 0.05 vs. mIgG control analyzed by the Mann–Whitney U test, two-way ANOVA, or one-way ANOVA. Representative data of an experiment of three independent experiments with consistent results. aANGPTL3, anti-ANGPTL3; aPD1, anti-PD1.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
ANGPTL3 levels are high in the peripheral blood of patients with AGC who progress after nivolumab treatment. Peripheral blood was collected from patients with AGC before and 1 month after initiating nivolumab therapy, and ANGPTL3 levels in plasma were measured by proteomic profiling or ELISA (n = 80). A, ANGPTL3 seq.10382-1 detected by proteomic profiling. B, ANGPTL3 seq.10391-1 detected by proteomic profiling. C, ANGPTL3 protein detected by ELISA. The median values for each group are shown in brackets. No significant differences were observed between pretreatment and posttreatment levels for any of the markers.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
ANGPTL3 levels are high in the peripheral blood of patients with AGC who progress after nivolumab treatment. Peripheral blood was collected from patients with AGC before and 1 month after initiating nivolumab therapy, and ANGPTL3 levels in plasma were measured by proteomic profiling or ELISA (n = 80). A, ANGPTL3 seq.10382-1 detected by proteomic profiling. B, ANGPTL3 seq.10391-1 detected by proteomic profiling. C, ANGPTL3 protein detected by ELISA. The median values for each group are shown in brackets. No significant differences were observed between pretreatment and posttreatment levels for any of the markers.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Summary of PFS and OS of the two groups divided by the cutoff values of ANGPTL3.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Summary of PFS and OS of the two groups divided by the cutoff values of ANGPTL3.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
ANGPTL3 data by ELISA (related to Figure 4)
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
ANGPTL3 data by ELISA (related to Figure 4)
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
High posttreatment ANGPTL3 levels are significantly associated with shorter OS of patients with AGC after nivolumab treatment. Patients were divided into two groups, high (red lines) and low (blue lines), based on ANGPTL3 cutoff values after treatment, and significant differences in PFS and OS were statistically analyzed by the Kaplan–Meier method and the Mantel–Cox log-rank test. A, ANGPTL3 seq.10382-1 detected by proteomic profiling. B, ANGPTL3 seq.10391-1 detected by proteomic profiling. C, ANGPTL3 protein detected by ELISA.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
High posttreatment ANGPTL3 levels are significantly associated with shorter OS of patients with AGC after nivolumab treatment. Patients were divided into two groups, high (red lines) and low (blue lines), based on ANGPTL3 cutoff values after treatment, and significant differences in PFS and OS were statistically analyzed by the Kaplan–Meier method and the Mantel–Cox log-rank test. A, ANGPTL3 seq.10382-1 detected by proteomic profiling. B, ANGPTL3 seq.10391-1 detected by proteomic profiling. C, ANGPTL3 protein detected by ELISA.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Data from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Anti-PD1/-PDL1 therapy has attracted great attention in cancer therapy in recent years, but a serious problem remains that only a small portion of patients can benefit from it. In this study, we attempted to identify a molecule that is associated with anti-PD1/-PDL1 therapeutic efficacy through proteomic profiling of plasma obtained from patients with advanced gastric cancer (AGC) receiving anti-PD1 nivolumab monotherapy. We collected peripheral blood from 91 patients with AGC before and after nivolumab treatment, and plasma was analyzed by the SomaScan v4.1 and ELISA. Relationships between the levels and patient prognosis were statistically analyzed. To evaluate antitumor effects induced by blocking the identified molecule for which high levels were significantly associated with poor prognosis, in vivo therapeutic experiments using mouse tumor models were conducted. Proteomic data revealed that the levels of 14 molecules both before and after treatment were significantly higher in patients with progressive disease (PD) than those in non-PD patients. Among them, angiopoietin-like 3 (ANGPTL3) levels were notably higher in PD patients than those in non-PD patients, and patients with high levels of ANGPTL3 either before or after treatment showed significantly worse prognosis. In mouse tumor models with increased ANGPTL3, anti-ANGPTL3 therapy significantly reduced tumor growth and synergistically enhanced anti-PD1 therapeutic efficacy. These suggest that high levels of ANGPTL3 in plasma are a significant risk factor associated with unresponsiveness to anti-PD1 treatment and poor prognosis. Targeting ANGPTL3 in the peripheral circulation may be a promising strategy to improve clinical outcomes in anti-PD1/-PDL1 therapy for AGC.Significance:This study provides valuable evidence suggesting the importance of targeting peripheral ANGPTL3 in the anti-PD1/-PDL1 therapy for AGC and will encourage and accelerate the development of a useful biomarker to predict responders/nonresponders to the therapy, leading to improved clinical outcomes in the treatment of gastric cancer.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Anti-PD1/-PDL1 therapy has attracted great attention in cancer therapy in recent years, but a serious problem remains that only a small portion of patients can benefit from it. In this study, we attempted to identify a molecule that is associated with anti-PD1/-PDL1 therapeutic efficacy through proteomic profiling of plasma obtained from patients with advanced gastric cancer (AGC) receiving anti-PD1 nivolumab monotherapy. We collected peripheral blood from 91 patients with AGC before and after nivolumab treatment, and plasma was analyzed by the SomaScan v4.1 and ELISA. Relationships between the levels and patient prognosis were statistically analyzed. To evaluate antitumor effects induced by blocking the identified molecule for which high levels were significantly associated with poor prognosis, in vivo therapeutic experiments using mouse tumor models were conducted. Proteomic data revealed that the levels of 14 molecules both before and after treatment were significantly higher in patients with progressive disease (PD) than those in non-PD patients. Among them, angiopoietin-like 3 (ANGPTL3) levels were notably higher in PD patients than those in non-PD patients, and patients with high levels of ANGPTL3 either before or after treatment showed significantly worse prognosis. In mouse tumor models with increased ANGPTL3, anti-ANGPTL3 therapy significantly reduced tumor growth and synergistically enhanced anti-PD1 therapeutic efficacy. These suggest that high levels of ANGPTL3 in plasma are a significant risk factor associated with unresponsiveness to anti-PD1 treatment and poor prognosis. Targeting ANGPTL3 in the peripheral circulation may be a promising strategy to improve clinical outcomes in anti-PD1/-PDL1 therapy for AGC.Significance:This study provides valuable evidence suggesting the importance of targeting peripheral ANGPTL3 in the anti-PD1/-PDL1 therapy for AGC and will encourage and accelerate the development of a useful biomarker to predict responders/nonresponders to the therapy, leading to improved clinical outcomes in the treatment of gastric cancer.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Proteomic profiling ranking data (related to Figure 1)
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
Proteomic profiling ranking data (related to Figure 1)
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
High plasma ANGPTL3 levels are significantly associated with poor prognosis of patients with AGC after nivolumab treatment. Patients were divided into two groups, high (red lines) and low (blue lines), based on ANGPTL3 cutoff values before treatment, and significant differences in PFS and OS were statistically analyzed by the Kaplan–Meier method and the Mantel–Cox log-rank test. A, ANGPTL3 seq.10382-1 detected by proteomic profiling. B, ANGPTL3 seq.10391-1 detected by proteomic profiling. C, ANGPTL3 protein detected by ELISA.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
High plasma ANGPTL3 levels are significantly associated with poor prognosis of patients with AGC after nivolumab treatment. Patients were divided into two groups, high (red lines) and low (blue lines), based on ANGPTL3 cutoff values before treatment, and significant differences in PFS and OS were statistically analyzed by the Kaplan–Meier method and the Mantel–Cox log-rank test. A, ANGPTL3 seq.10382-1 detected by proteomic profiling. B, ANGPTL3 seq.10391-1 detected by proteomic profiling. C, ANGPTL3 protein detected by ELISA.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
In vivo therapeutic experiments using other tumor models (related to Figure 4)
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer
In vivo therapeutic experiments using other tumor models (related to Figure 4)